In addition
to our focus on the U.S.
clinical program, the company
has been very proactive in the area of partnering
and licensing. To date, the company has completed
agreements with five key partners: Alkem Laboratories
(India), Drug Enhancement Corporation of America
(DECA), China Bao Tai, Walco and Bayer Animal
Health. As well, discussions continue with
a number of prospective partners for the licensing
of Microcyn for healthcare and other applications.
Alkem Laboratories:
In 2006, Alkem Laboratories,
one of India’s top 10 pharmaceutical companies,
licensed the rights to the Microcyn Technology
in India for use in wound care. Alkem has an
impressive track record of building major brands
with doctors and consumers. Alkem has commercialized
its Microcyn wound care product under the brand
name Oxum, its launch being the premier marketing
event for Alkem in 2006.
Union
Springs Pharmaceuticals :
In June of 2007, Oculus
entered into an exclusive licensing agreement
with Union Springs Pharmaceuticals, under which
Oculus licensed rights to its Microcyn® Technology
for use in an over-the-counter first responder “pen-like” applicator
intended for use by police, fire, military, emergency
medical personnel, healthcare providers, homeland
security personnel and consumers.
MyClyns™ is a topical post-exposure protection
device that provides for a versatile, convenient
and readily accessible first response spray.
China Bao Tai:
In April of 2007, Oculus
entered into an exclusive distribution agreement
with China Bao Tai Investment Company, Ltd.,
for the rights to its Microcyn®-based
wound care solution in China. The Microcyn Technology
will be packaged under China Bao Tai’s
private label brand names in China.
China Bao Tai will utilize
various sub-distributors for hospitals, independent
pharmacies and retail pharmacies. To that end,
China Bao Tai has reached agreement with two
sub-distributors:
- Sinopharm
for hospital and pharmacy distribution:
Sinopharm is China's
largest pharmaceutical group. Incorporating
research with production and service trade,
the company has under its jurisdiction 10 wholly
owned subsidiaries or shareholding companies.
- Lianhua
Supermarkets for supermarket distribution:
Lianhua Supermarket
Holdings Co., Ltd. is a retail chain operator
with retail outlets covering the entire Chinese
nation, offering a full range of products through
direct operations, franchises, mergers and
acquisitions. Lianhua Supermarket operates
a total of 3,609 outlets spanning 21 provinces
and municipalities across the nation.
China Bao Tai has completed
two randomized controlled clinical trials of
shelf-stable Microcyn® Technology
in China, a 162-patient burn wound study and
a 35-patient chronic would treatment study. This
trial data was submitted to the Chinese State
Food and Drug Administration (SFDA) in December
2007 and marketing approval was granted by the
agency in March of 2008. Preparations are now
underway for commercialization of the Microcyn
Technology in China.
Bayer
Animal Health:
In June 2008, Oculus entered into agreements
with Bayer Australia Limited and Bayer (Sichuan)
Animal Health Co. Ltd., for development of the
Microcyn Technology for use in the Australian
and Chinese animal health markets respectively.
Upon receipt of necessary regulatory approvals,
Bayer retains right of first negotiation to enter
into a distribution agreement for Oculus’ Vetericyn™ animal
brand (formulated with the Microcyn Technology)
in those countries.
Walco:
In January 2008, Oculus entered into an exclusive distribution agreement
with Walco, a subsidiary of Animal Health International, Inc., for the
rights to its Microcyn®-based Vetericyn™ Wound Spray for animals in North
America. Walco is currently engaged in an animal study using the Vetericyn
Wound Spray in an effort to better understand the production animal wound
care market while also obtaining clinical evidence of safety and efficacy
for use in marketing. |
